商报讯(通讯员林倩黄舒婷记者汪晓筠)家门口的小药店靠不靠谱？医美诊所用的药品是否安全？这些老 百姓日常最关心的细节，正成为余杭区药品监管领域治理的重点。今年以来，余杭区市场监管局启动针 对"三小"(小药店、小诊所、小美容店)的药品安全专项治理，旨在清理群众身边的不正之风，默默守护 市民的健康生活。 数字画像 监管更"聪明" 小药店、小诊所、小美容店业态复杂、数量众多、变更频繁、风险隐患易发。要想厘清这本监管"台 账"，必须做到精准画像+动态管理。 通过深度整合"审评审批系统"、跨部门数据资源，区市场监管局采取"线上筛查+线下核查"双轨并行方 式，为全区1155家"三小"单位建立了动态电子档案——包括313家小药店、182家小诊所和660家小美容 店。 三张清单 整改不留死角 检查不是走过场，余杭区市场监管局建立"主体信息清单+问题清单+整改清单"的闭环机制：从摸排到 检查、从问题到整改，全部线上留痕、实时跟踪。截至目前，发现的132个问题均已100%完成整改。 药品安全无小事，区市场监管局高度重视。据余杭区市场监管局工作人员介绍："行动开展以来，局领 导带队'查店'8次，全区依法处罚30家单位，包括14家小美 ...

华润医药公布中期业绩。集团总收益为人民币1318.668亿元，同比增长2.5%。其中，医药分销占比最 高，达79.2%，其次是制药业务(16.6%)和药品零售(4.2%)。 集团毛利为人民币215.096亿元，同比增长2.8%，整体毛利率为16.3%。净利润为人民币50.536亿元，同 比下降8.8%；公司拥有人应占溢利为人民币20.773亿元，同比减少20.3%。剔除一次性项目影响，净利 润和公司拥有人应占溢利分别同比略降1.3%和4.7%。每股基本盈利为人民币0.33元，董事会宣派每股中 期股息人民币0.072元。 ...

Core Insights - China Resources Pharmaceutical (03320) reported a mid-year performance for 2025, achieving revenue of RMB 131.867 billion, a year-on-year increase of 2.54% [1] - The company's profit attributable to equity shareholders was RMB 2.077 billion, a decrease of 20.25% year-on-year, with earnings per share at RMB 0.33 and an interim dividend proposed at RMB 0.072 per share [1] - The gross profit for the reporting period was RMB 21.5096 billion, up 2.8% from RMB 20.934 billion in the same period last year, maintaining a gross margin of 16.3% [1] Revenue Breakdown - The revenue contributions from the three main business segments were 16.6% from pharmaceuticals, 79.2% from medical distribution, and 4.2% from retail and other operations [1] - The company has a total of 83 production bases and 561 production lines, producing 944 products, with 555 products included in the national medical insurance catalog and 235 products in the essential drug list [1] Profitability Metrics - Excluding the impact of impairment and other one-off items, the net profit for the reporting period saw a slight decline of 1.3%, while the profit attributable to the company's owners decreased by 4.7% year-on-year [1]

Core Viewpoint - China Resources Pharmaceutical (03320) reported a revenue of RMB 131.867 billion for the first half of 2025, representing a year-on-year increase of 2.54% [1] Financial Performance - The profit attributable to equity shareholders was RMB 2.077 billion, a decrease of 20.25% year-on-year [1] - Earnings per share stood at RMB 0.33, with an interim dividend proposed at RMB 0.072 per share [1] - Gross profit for the period was RMB 21.5096 billion, up 2.8% from RMB 20.934 billion in the same period last year [1] - The overall gross margin remained stable at 16.3%, unchanged from the first half of 2024 [1] - Excluding impairment losses from associates and other one-off items, net profit decreased slightly by 1.3% year-on-year, while profit attributable to the company's owners fell by 4.7% [1] Business Segmentation - Revenue contributions from the three main business segments were as follows: Pharmaceuticals at 16.6%, Medical Distribution at 79.2%, and Retail Pharmacy and Others at 4.2% [1] - As of the end of the reporting period, the company operated 83 production bases and 561 production lines, producing 944 products, of which 555 are included in the National Medical Insurance Catalogue and 235 in the Essential Drug List [1]

8月18日，在海南博鳌举行的西普会上，山东信宏仁医药凭借卓越的综合实力与区域战略布局，入围"2025中国药品零 售综合竞争力百强榜"及"山东中部城市群竞争力十强"，董事长张超作为行业领军者代表登台领奖。 信宏仁医药此次入围"2025中国药品零售综合竞争力百强榜"第39位，既是对其精细化运营能力与持续增长韧性的专业 认证，更印证了企业在医药零售价值重构期的战略前瞻性。此外，该企业同步获得"山东中部城市群竞争力十强"称 号，凸显其通过构建区域协同网络，形成应对市场变革的核心壁垒，为行业精耕细作转型提供标杆样本。 上述荣誉标志着信宏仁医药正在从"规模扩张"到"质量发展"转型，逐渐成为中国药品零售行业迈向高质量发展的一支 新锐力量。 本届西普会以"快蜕变.穿越新周期——增长元动力重构与产业生态进化"为主题，中康产业研究院通过七力评价模型 (经营规模、运营效率、品牌影响、专业服务、利润创造、成长性、创新引领)，对全国药品零售企业进行全维度量化 评估。数据显示，本届百强榜年销售门槛达4.5亿元，覆盖27个省市自治区，其中广东、山东等五省入围企业超6家， 产业集群效应显著。 ...

很多家庭有囤药习惯，但一旦过期，药品的化学成分、有效性等可能发生改变。有数据显示，我国约有 78.6%的家庭存有备用药品，全国每年产生过期药品预计达1.5万吨。面对如此庞大的"有毒垃圾"，相关 回收处理机制却长期缺位。比如，药品管理法对药品生产、销售、使用都做了明确要求，但对于过期药 品特别是零散家庭过期药品的回收处理缺乏具体规定。许多家庭即便有心想科学处置过期药，往往还挺 费劲，才能找到正规回收点。 值得注意的是，家庭过期药品的安全退出，需要完善回收体系，也在于更新用药理念。从过往经验看， 很多过期药来源于囤药过度。一些药店、药房为推销药品"玩花招"，以"充卡优惠"等吸引老年人，加剧 了资源浪费。从源头减少无谓浪费，减轻回收的压力，需要推动药品按需采购、提升公众理性备药意 识，同时引导企业减少不必要的促销和包装，这也是实现安全、绿色药品管理不可忽视的一环。 吃，已然不能吃；扔，不能随便扔，家庭过期药如何处理一直是个老大难。近日，北京部分社区推出定 点回收、定期上门等多种旧药回收服务，让过期药能够"安全退场"。 用心设计流程、贴近民生需求，处理过期药的老大难将得到解决。当然，更重要的，是推动形成全民参 与、人 ...

Core Viewpoint - The Fujian Provincial Drug Administration conducted flying inspections on 40 pharmaceutical companies and usage units to enhance drug circulation safety and ensure public medication safety [2][4]. Group 1: Inspected Retail Enterprises - A total of 20 retail pharmaceutical enterprises were inspected, including both single retail enterprises and retail chain stores [2]. - Notable companies inspected include Fuzhou Chunyangtang Health Management Co., Ltd. and Xiamen Yanhua Pharmacy Co., Ltd. [2]. Group 2: Inspected Usage Units - 20 pharmaceutical usage units were also inspected, comprising public medical institutions, individual clinics, and village health stations [3]. - Key institutions inspected include the Xiadou Street Community Health Service Center and the Jinjiang Traditional Chinese Medicine Hospital [3]. Group 3: Inspection Focus - The inspections focused on the quality management system, purchasing and sales channels, computer systems, storage and transportation, financial transactions, prescription drug sales, and online sales channels [4]. - Vaccine storage and transportation management were specifically emphasized for vaccination units [4]. Group 4: Inspection Results - Retail enterprises exhibited issues such as outdated quality management systems, improper drug display and storage, and non-compliance with prescription drug sales regulations [5]. - Usage units faced problems with inadequate storage conditions, lack of temperature monitoring equipment, and incomplete records for cold chain transportation [6]. Group 5: Follow-up Actions - Issues identified during inspections have been referred to local drug regulatory departments for further investigation and corrective actions [7].

Group 1 - The latest stock price of Shuyupingmin is 13.07 yuan, an increase of 0.22 yuan from the previous trading day's closing price, representing a rise of 1.71% [1] - The stock opened at 12.85 yuan, reached a high of 13.15 yuan, and a low of 12.81 yuan, with a trading volume of 51,659 hands and a transaction amount of 0.67 billion yuan [1] - Shuyupingmin operates in several concept sectors including pharmaceutical commerce, Shandong sector, medical beauty, cold chain logistics, and Shenzhen Stock Connect [1] Group 2 - The company primarily engages in the retail chain operation of pharmaceuticals, mainly selling drugs, medical devices, and health products [1] - Recent regulations regarding self-service medicine dispensing machines have raised industry concerns, with a draft proposal allowing these machines to dispense prescription drugs and Class A non-prescription drugs, leading to worries about changes in the competitive landscape [1] - Industry insiders noted that the operational costs of self-service dispensing machines are significantly lower than traditional pharmacies, which may disrupt existing retail pharmacy business models [1] Group 3 - There are differing opinions on the regulation of self-service dispensing machines, with some advocating for strict limitations to Class B non-prescription drugs, while prescription drug sales should continue to adhere to existing regulatory requirements [1] - On August 19, 2025, Shuyupingmin experienced a net outflow of 2.1911 million yuan in main funds, accounting for 0.07% of its circulating market value [1] - Over the past five days, the net outflow of main funds reached 17.4921 million yuan, representing 0.55% of its circulating market value [1]

Group 1 - The local market supervision administration held a meeting with the heads of 9 retail pharmaceutical companies to discuss the standardization of drug and medical device management [1][3] - Key provisions of the Drug Administration Law and Drug Quality Management Standards were explained, focusing on issues that may arise during the procurement, acceptance, storage, maintenance, and sales of drugs and medical devices [3] - Companies were required to immediately rectify any identified issues and enhance employee training while improving operational systems [3] Group 2 - The administration plans to implement a combination of daily inspections, special checks, and unannounced inspections to monitor compliance in drug and medical device operations [3] - Strict legal actions will be taken against any violations discovered during these inspections [3]

Core Viewpoint - Yifeng Pharmacy's stock price has decreased by 2.20% to 23.96 yuan, with a trading volume of 2.17 billion yuan, indicating market volatility and investor sentiment [1] Company Overview - Yifeng Pharmacy primarily engages in drug retail and health services, covering pharmaceutical commerce and domestic circulation [1] - The company has expanded its store scale through acquisitions, with operations spanning multiple provinces and cities across the country [1] Recent Developments - The controlling shareholder and concerted parties have recently reduced their holdings by 24.248 million shares, accounting for 2% of the total share capital, realizing approximately 555 million yuan [1] - The reduction includes a core employee shareholding platform, resulting in a decrease of their holding ratio to 32.85% [1] - Company executives have also previously engaged in share reductions [1] Financial Performance - In Q1 2025, the company's net profit increased by 10.51% year-on-year, while revenue growth slowed to 0.64%, reflecting a decline compared to previous years [1] Market Activity - On the day of reporting, Yifeng Pharmacy experienced a net inflow of 1.02 million yuan in main funds, but over the past five days, there was a net outflow of 11.8944 million yuan [1]